Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the...
Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration...
Recently, Everest Medicines has announced another positive development. The company’s lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the...
